Literature DB >> 21883030

Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.

Jiri Minarik, Vlastimil Scudla, Tomas Tichy, Tomas Pika, Jaroslav Bacovsky, Pavel Lochman, Josef Zadrazil.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883030     DOI: 10.3109/10428194.2011.619610

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Portal hypertension related to light chain deposition disease of liver: an enlightening experience.

Authors:  Arunansu Talukdar; Kabita Mukherjee; Dibbendhu Khanra; Manjari Saha
Journal:  BMJ Case Rep       Date:  2013-05-29

2.  Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male.

Authors:  Bappa Adamu; Mushabab Al-Ghamdi; Mustafa Ahmad; Khaled O Alsaad
Journal:  Case Rep Nephrol       Date:  2016-12-19

3.  [Clinical features and prognosis of patients with primary light chain deposition disease].

Authors:  J N Wang; J Feng; X X Cao; M H Duan; L Zhang; D B Zhou; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

4.  Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone.

Authors:  Di Wang; Yan Wang; Shiren Sun
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

Review 5.  Treatment of Light Chain Deposition Disease: A Systematic Review.

Authors:  Adeel Masood; Hamid Ehsan; Qamar Iqbal; Ahmed Salman; Hamza Hashmi
Journal:  J Hematol       Date:  2022-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.